Loading patent…
AssigneeBioneer Corporation
InventorsSu Han Song, Sun Kyung Kang, Jae Ho Kim, Young Hyun Park, Han Oh Park
Estimating the term…
The present invention relates to microorganisms for preventing or treating obesity or diabetes mellitus which have excellent viability and produce polysaccharides efficiently in the intestines, more particularly, is directed to microorganisms for preventing or treating obesity or diabetes mellitus, which are capable of reducing the amount of monosaccharides or disaccharides that can be absorbed into the intestine by converting those mono or disaccharides into polymeric materials that cannot be absorbed in the intestines. The present invention is also directed to a pharmaceutical composition containing pharmaceutically effective amount of the microorganisms and a food composition containing the microorganisms as an active ingredient.
Lactobacillus reuteri PRD202(KCTC-10301BP) which produces polysaccharides.
Lactobacillus fermentum NM316(KCTC-10458BP) which produces polysaccharides.
A pharmaceutical composition for preventing or treating obesity comprising an pharmaceutically effective amount of Lactobacillus reuteri PRD202(KCTC-10301BP) which produces polysaccharides and a carrier.
A food composition comprising Lactobacillus A food composition comprising Lactobacillus reuteri PRD202 (KCTC-10301BP) which produces polysaccharides as an active principle.
A pharmaceutical composition for preventing or treating diabetes mellitus comprising an pharmaceutically effective amount of Lactobacillus reuteri PRD202 (KCTC-10301BP) which produces polysaccharides and a carrier.
A pharmaceutical composition for preventing or treating obesity comprising an pharmaceutically effective amount of Lactobacillus fermentum NM316 (KCTC-10458BP) which produces polysaccharides and a carrier.
A food composition comprising Lactobacillus fermentum NM316 (KCTC-10458BP) which produces polysaccharides as an active principle.
A pharmaceutical composition for preventing or treating diabetes mellitus comprising an pharmaceutically effective amount of Lactobacillus fermentum NM316 (KCTC-10458BP) which produces polysaccharides and a carrier.
Dependencies are inferred from the claim text.